Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What happened to the hiv drug they had years ago.
Sangamo participates in a conference call with Truist Conference call with management will be held on December 11 at 12 pm hosted by Truist
Read more at:
https://thefly.com/n.php?id=3207168
I loaded next weeks. The $15’s I bought at .35 today closed over $2.
I’m hoping for continuation into tomorrow to sell into. 10X your money is too hard to pass up if I can get it!
Nice! There are lotto calls which are my crack and then there are longer term options which can be very profitable.
GL Brother!
May I ask you what time period you chose for your call options?
Thanks
LOL Ain't that the Truth my Friend! That's how it Rolls in options! :) Now I'm hoping my KODK January calls pay off for me! LOL I took a decent profit on my KODK December 18th calls on that last pop. Those went from .05 cents to over $1.50 for me. If they get the loan approval before then I will be in the Money on my new calls! Fingers Crossed!!!
God I hope it is a buyout, I literally bought every Call option I could. $15 $16 and $17 for next friday.
A buyout at $20-$25 would make my year lol!
DT it got to $13 lol! Just took a little longer than expected...
I bought an ass load more of Calls here! $SGMO
Finally is right. I am glad I was patient. Could we see $20s soon? We get bought by Pfizer?
I agree! I have options that are going to expire tomorrow, but I think this is a great long-term investment. I was really hoping for some sort of Big rally by the end of the week, but that seems to be fading for my calls. I still like this company though. Lots of potential here.
Took at starter almost a billion in cash I'm in heavy.
Great Partnerships.
$SGMO
Come on SGMO Move up to around $13 for me and I will be very happy!
I wonder why SGMO has gone down so much in the last two trading sessions? The open interest is still insane on the July $13 calls. I got my fingers crossed here as I got some $12 calls for July!
PFE is a partner with SGMO in Hemo. PFE CEO telegraphed to participants at a Goldman Sachs conf earlier this week that favorable or positive data was forthcoming. SGMO had announced they would be releasing data on the 18th....so you can be the judge. Huge call buying in July 13's
jim pappa
@jim_pappa
Replying to
@MWM76
and
@fezziwig2019
$PFE ceo has stated that they will be making comments on their gene therapy plans next week — which is leading to speculation on their work with $SGMO
per Twitter poster...
Something seems to be brewing at SGMO. Recent price runup. Directors exercising shares. Biogen funding & neurogenetic research starting. ZFN 2.0. Lots of positive signs.
$SGMO Today"s volume , 5.5 mil, is the 5th highest volume day for the last 12 months, and shorts only backed it up a penny today. There's not only retail and pro shorts, but the market makers as well are short, today leading up to tomorrow's huge conference. Squeeze is on This is a $100.00 stock in a year or two. Special Announcement will dropped another partnership with a new blue chip biotech
Biogen just bought 17% of the company in one of the largest biotech deals in history
https://finance.yahoo.com/news/sangamo-therapeutics-announces-participation-upcoming-133000246.html
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
Cowen 40th Annual Health Care Conference
Presentation Date: Wednesday, March 4th at 10:00 a.m. Eastern Time
Location: Boston, MA
Barclays Global Healthcare Conference
Presentation Date: Wednesday, March 11th at 8:30 a.m. Eastern Time
Location: Miami, FL
Presentations will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will also be available on the Sangamo website after the event.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and genome regulation. For more information about Sangamo, visit www.sangamo.com.
$SGMO
The Deal With Biogen Boosts The Recommendation To Buy Sangamo Shares
Mar. 2, 2020 8:51 AM ET|9 comments | About: Sangamo Therapeutics, Inc. (SGMO), Includes: BIIB
The new estimate for cash runway goes to five years.
Biogen will own 17% of Sangamo, future buyout potential emerges.
Sangamo's undervalued condition is even more apparent.
The recommendation update
Biogen Inc. (BIIB) and Sangamo's Therapeutics Inc. (SGMO) agreement have eclipsed my recommendation found in my recent article. Despite adding 24M to 116M outstanding shares, Biogen as the largest shareholder of Sangamo offers a strong hint that the company is, in fact, on the radar of big pharma. Substantial equity ownership by Biogen could serve as a springboard to the acquisition of the company under the right financial circumstances.
A central nervous system (NYSE:CNS) partnership, which I thought initially would take place in 2021, adds confidence to the investment thesis. Since Biogen is buying shares at $9.21, this is a very comfortable upper limit to be used for accumulation. I expect shares to trade in double digits, even before Pfizer's phase 3 trial or SB-525 updates are publicized.
The deal for Alzheimer's and Parkinson's, plus one not identified target, adds $350M to Sangamo's coffers, which had about $385M at the end of 2019, based on the Q4 release. In the past, the cash runway was expected to last to the end of 2021, and with the new money, I assume, Sangamo can operate until the end of 2023. Pfizer's objective to commercialize an SB-525 program as gene therapy for hemophilia A is expected to deliver $275M in milestones by 2022. Provided milestone payments are coming from Gilead Inc. (GILD) and Sanofi (SNY), which just paid for dosing of a first patient in the sickle cell disease trial, Sangamo appears to be funded for the next five years.
Sangamo's partners, Gilead, Pfizer Inc (PFE), Takeda Pharmaceutical Company Limited (TAK), Sanofi, and now Biogen, paid for collaboration with Sangamo because of the compelling science, offering the best form of validation for retail investors. Still, what is apparent, besides now broken thesis that the company is running out of cash, Sangamo continues to be the most undervalued member of the edit and gene therapy' group of companies (table below).
Adjusted for new shares, Sangamo is just below the market capitalization of Editas (EDIT), a CRISPR gene edit company, which has not dosed a single patient yet, and already discussed in my previous article uniQure (QURE).
The Biogen deal illustrates a deep discount
Biogen purchased a genome regulation platform to produce a cure for a patient population of six million. A page from the gene therapy book on pricing produces, at $1M per treatment, a $6 trillion market opportunity, of course, when the treatment works. Even the middle of the road royalty at 9% would offer Sangamo a mind-boggling $540B in payments. If the application is better than the current standard of care but has limitations, and the condition has reduced the market opportunity by 90%, Sangamo would still receive around $50.4B in royalties.
Sangamo's war chest of possible milestone payments, worth about $6B, does not have a much better understanding. On February 28th, Sangamo's market capitalization neared $1.2B, after I included Biogen shares in the calculation. In this scenario, after the deduction of $605M in cash or equivalents expected by the end of Q2 2020, the $6B associated with partnered programs would be worth only $590M, and those without the partnership, like Fabry or MPS II, would have zero value.
Other updates
The company held a Q4 call on February 28th. We have learned that the Fabry program will deliver results by the end of 2020 or early 2021. While the company was tight-lipped on details, the entire process appears much more disciplined in the design and preparation of the study. The company has not enrolled patients yet, because the process rejected more patients than anticipated. Bettina M. Cockroft, Senior V.P. & Chief Medical Officer Sangamo, offered following on the Fabry trial:
"So we've initiated six sites in the U.S. and actually participated in the initiation of the seventh site in London on Monday this week. So we're currently screening patients. And it's my priority, above all, to ensure the quality of the study by ascertaining that the right patients are included. And so we have screened several patients, some of whom had borderline exclusion criteria and who are the screen failed. Indeed, we've had more screen failures than we were expecting at the outset of the trial, but other patients continue to be in the screening phase. And just as a reminder, screening can take up to 2 months to complete. So we've also introduced protocol amendments that will optimize the inclusion criteria and will allow us to optimize those as well as address the FDA's recent guideline on - guidance on Fabry disease."
Separately, Pfizer has replaced Sangamo as a sponsor of the phase 2 trial of SB-525 on clincialtrials.gov, and it is recruiting two more patients, mirroring the seven patients' count of BioMarin's phase 2 trial. This specific move helps my belief that Pfizer will take the same approach to BLA as BioMarin. I expect the progression to reach the accelerated review four months sooner than BioMarin, based on the rapid uptake of SB-525. My anticipated date for Pfizer to file BLA is February 2021.
Fellow investor and S.A. author, Marty Chilberg, analyzed the most recent FDA guideline on the sameness of gene therapy. A different vector in the same viral class would be reviewed on a case-by-case basis to determine the condition of unique treatment. Sangamo's adeno-associated virus combination of AAV2/AAV6 is likely differentiated enough from AAV5 used by BioMarin to support such a status. Still, the mechanism of uptake and hopefully durability will be equally speaking for it.
Adrian Woolfson, Head of Research and Development for Sangamo, confirmed Pfizer would be updating on progress in hemophilia A:
"We were in regular contact with Pfizer about the hemophilia A study. They remain incredibly enthusiastic, as do we. Pfizer will provide the next update, and it's probably best if we leave it for them to announce when that happens."
The CEO, Sandy Macrae also commented:
"I know they are eager to share the data when it reaches the important time points because they want to make sure that we are all aware of the advantages of this asset."
I prefer Sangamo focused on delivering work in the clinic instead of a narrative of the possibilities and the giveaway of time for updates. The element of surprise, like the announcement of the Biogen deal, is much healthier, and I favor this approach over the road map of conferences and updates handed to short sellers.
Conclusion
I recommend Sangamo as a buy with $9.21 as an upper limit for accumulation, even though I believe this number is quite conservative. I continue to expect $17 to $18 by the end of the year, based on already described milestones and also including added shares. I still see Fabry adding $1B to the market capitalization. If all pieces fall into the right place, a 2021 target of $25 per share or the market capitalization of $3.5B is very realistic. Also, I feel Sangamo could make another surprise announcement for the pre-clinical program like Colitis or Multiple Sclerosis within the next 12 months; however, I do not expect equity offering as part of it.
$SGMO
Gilead, Sangamo strike $3B off-the-shelf CAR-T deal
Kite is paying Sangamo $150 million upfront and committing to $3 billion in milestones.
Gilead’s Kite has struck a $3 billion deal to access Sangamo Therapeutics’ zinc finger nuclease (ZFN) technology. Kite will use the ZFN gene editing platform to create next-generation, off-the-shelf CAR-T therapies to cement its position as a long-term front-runner in the growing cell therapy space.
Sangamo is giving Kite the exclusive right to use its ZFN platform to create allogeneic and autologous anticancer cell therapies. For Kite, that expands the toolkit it can apply to its R&D projects while also serving to keep the technology out of the hands of Novartis, Celgene’s Juno and the other CAR-T runners and riders.
In return, Kite is paying Sangamo $150 million upfront and committing to $3 billion in milestones. The milestones are tied to the success of 10 or more products that could potentially use Sangamo’s technology.
Full details of how those pipeline prospects will differ from the first wave of CAR-T therapies are yet to emerge. But Gilead’s release put a discussion of the potential to use the gene-editing technology in off-the-shelf cell therapies up top. As Gilead noted, off-the-shelf cell therapies eliminate the need to process a patient’s own cells, thereby cutting the time it takes for them to receive an infusion.
Cellectis, with the support of Pfizer and Sevier, is betting that benefit, plus the simplified logistics and linked effect on cost of production, will enable its off-the-shelf CAR-T cell therapies to come from behind and capture the market. The French biotech built its R&D strategy around the TALEN editing platform, while Novartis and Juno are using CRISPR/Cas9 to power their next-generation pipelines.
RELATED: Kite's CAR-T medication, cancer candidates draw choosy Gilead
ZFN has been around for longer than CRISPR/Cas9 and was put in the shade by the breathless hype around the latter technology. But Sangamo has continued plugging away at the platform, bringing it to the point that it has a ZFN drug in the clinic and a landmark deal with Gilead. The deal gives Sangamo near and potentially long-term cash boosts, while also validating its belief in ZFN.
“We believe Sangamo’s zinc finger nucleases provide the optimal gene editing platform, and we look forward to working with Sangamo to accelerate our efforts to develop next-generation autologous cell therapies, as well as allogeneic treatments that can be accessed more conveniently in the hospital setting for people living with cancer,” Gilead CEO John Milligan, Ph.D., said in a statement.
$SGMO
We will see a bidding war for this company Pfizer and Biogen Also partnered with KITE, Sanofi & Takedo
https://investor.sangamo.com/news-releases/news-release-details/sangamo-announces-early-completion-transfer-pfizer-sb-525
Biogen puts down massive $350M upfront for Sangamo preclinical assets
https://www.fiercebiotech.com/biotech/biogen-puts-down-a-massive-350m-upfront-for-sangamo-preclinical-assets
https://www.sangamo.com/collaborations
$SGMO
More clinical updates and Analysts upgrades coming Biogen now owns% of SGMO $350 Million up front with possible 2-3 Billion royalties. This is just on a few of sgmo trials there is a wide array of trials in gene editing field. Cash runway into 2023 Biogen will buy them before that.
https://www.sangamo.com/pipeline
$SGMO
SGMO - BIIB Global Neuro Deal Validates ZNF Gene Editing - BUY - In one of the largest preclinical deals in biotech history, Biogen will pay Sangamo $350 million upfront and up to very achievable $2.37 billion in potential milestones. The deal vindicates and validates SGMO’s ZNF platform in gene editing, which most investors have written off. With current cash ~$700 million, SGMO is cheaper than ever to us on multiple valuation methodologies, either as a standalone and even so when compared to other gene editing stocks.
$SGMO
SGMO - BIIB Global Neuro Deal Validates ZNF Gene Editing - BUY - In one of the largest preclinical deals in biotech history, Biogen will pay Sangamo $350 million upfront and up to very achievable $2.37 billion in potential milestones. The deal vindicates and validates SGMO’s ZNF platform in gene editing, which most investors have written off. With current cash ~$700 million, SGMO is cheaper than ever to us on multiple valuation methodologies, either as a standalone and even so when compared to other gene editing stocks.
$SGMO
https://investor.sangamo.com/news-releases/news-release-details/biogen-and-sangamo-announce-global-collaboration-develop-gene
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
February 27, 2020 at 4:06 PM EST
Download PDF
Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a neuromuscular target, with exclusive rights for nine additional undisclosed neurological targets
Biogen will pay Sangamo $350 million upfront, including a license fee and an equity investment in Sangamo stock
Sangamo is eligible to receive up to $2.37 billion in potential milestones, as well as royalties on potential net commercial sales
Biogen’s access to Sangamo's gene regulation therapies complements its expanding efforts in gene therapy across diverse neurological diseases
CAMBRIDGE, Mass. & BRISBANE, Calif.--(BUSINESS WIRE)-- Biogen Inc. (Nasdaq: BIIB) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets. The companies will leverage Sangamo’s proprietary zinc finger protein (ZFP) technology delivered via adeno-associated virus (AAV) to modulate the expression of key genes involved in neurological diseases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200227005961/en/
“As a pioneer in neuroscience, Biogen will collaborate with Sangamo on a new gene regulation therapy approach, working at the DNA level, with the potential to treat challenging neurological diseases of global significance. We aim to develop and advance these programs forward to investigational new drug applications,” said Alfred Sandrock Jr., M.D., Ph.D., Executive Vice President, Research and Development at Biogen.
“There are currently no approved disease modifying treatments for patients with many devastating neurodegenerative diseases such as Alzheimer’s and Parkinson’s, creating an urgency for the development of medicines that will not just address symptoms like the current standards of care, but slow or stop the progression of disease,” said Sandy Macrae, CEO of Sangamo. “We believe that the promise of genomic medicine in neuroscience is to provide a one-time treatment for patients to alter their disease natural history by addressing the underlying cause at the genomic level.”
Sangamo’s genome regulation technology, zinc finger protein transcription factors (ZFP-TFs), is currently delivered with AAVs and functions at the DNA level to selectively repress or activate the expression of specific genes to achieve a desired therapeutic effect. Highly specific, potent, and tunable repression of tau and alpha synuclein has been demonstrated in preclinical studies using AAV vectors to deliver tau-targeted (ST-501) and alpha synuclein-targeted (ST-502) ZFP-TFs.
“The combination of Sangamo’s proprietary zinc finger technology, Biogen’s unmatched neuroscience research, drug development, and commercialization experience and capabilities, and our shared commitment to bring innovative medicines to patients with neurological diseases establishes the foundation for a robust and compelling collaboration,” said Stephane Boissel, Head of Corporate Strategy at Sangamo. “This collaboration exemplifies Sangamo’s commitment to our ongoing strategy to partner programs that address substantial and diverse patient populations in disease areas requiring complex clinical trial designs and commercial pathways, therefore bringing treatments to patients faster and more efficiently, while deriving maximum value from our platform.”
Under the terms of the collaboration, Biogen has exclusive global rights to ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a third undisclosed neuromuscular disease target. In addition, Biogen has exclusive rights to nominate up to nine additional undisclosed targets over a target selection period of five years. Sangamo will perform early research activities, costs for which will be shared by the companies, aimed at the development of the combination of proprietary CNS delivery vectors and ZFP-TFs targeting therapeutically relevant genes. Biogen will then assume responsibility and costs for the investigational new drug-enabling studies, clinical development, related regulatory interactions, and global commercialization.
Sangamo will be responsible for GMP manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity. Biogen will assume responsibility for GMP manufacturing activities beyond the first clinical trial for each of the first three products.
Upon closing of this transaction, Sangamo will receive $350 million comprised of $125 million in a license fee payment and $225 million from the sale of new Sangamo stock, or approximately 24 million shares at $9.21 per share. In addition, Sangamo may receive up to $2.37 billion in other development, regulatory, and commercial milestone payments, including up to $925 million in pre-approval milestone payments and up to $1,445 million in first commercial sale and other sales-based milestone payments. Sangamo will also be eligible to receive from Biogen tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration. Closing of the transaction is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the U.S.
About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology, and pain.
Biogen routinely posts information that may be important to investors on its website at www.biogen.com. To learn more, please visit www.biogen.com and follow Biogen on social media – Twitter, LinkedIn, Facebook, YouTube.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com.
$SGMO
SGMO has major potential just signed huge deal with Biogen giving them cash into 2023 Deep pipeline top Gene Editing company in the world will be worth more than Crisper soon
One needs to think of the patient population. The R&D presentation had 5M Alzheimer's patients and Parkinson's was 1M. A genome regulation would be likely priced as gene therapy, at $1M. The market potential is about $6 Trillion. At 9% royalty, think $540B to Sangamo. agreement means to Sangamo. BTW Biogen shares are in an escrow, cannot be sold for one year, and then they may be sold in 50% drops until 5% is reached.
Biogen is also forbidden to buy shares on the open market, just in case they want to take over, or worse sell short own holding.
Pfizer is adding two patients to phase 2 to copy BioMarin 7 patients and have a mirror image. Judging by the moves of BioMarin, Pfizer could be filing BLA by February 2021. Between now and then, data drops to keep BioMarin at bay would be likely. At $10, including Biogen investment, the stock is worth $1.4B. Biogen did not select CRSP for it, as the method cannot make precise regulation. Vertex sold half shares of CRSP, but WS barrel fish bought up CRSP to over $4.2B. That's $33 for Sangamo share. None of the CRSP deals are like the ones for Sangamo, and Vertex seems to be moving out, not because it needs money.
Keep your shares, people,
17% shares in Biogen's hands. That is the point. Shorts are not getting those shares. Equity investment is much more attractive than selling to the markets, and shorts to cover. Sangamo is getting $350M, and secures cash runway for another two years, in worse case 2023.
https://www.sangamo.com/pipeline
$SGMO
* * $SGMO Video Chart 02-28-2020 * *
Link to Video - click here to watch the technical chart video
More like earth shattering. In a better environment we'd double on this news. Often these generous statements of confidence are a precursor to a buyout.
https://finance.yahoo.com/news/biogen-sangamo-announce-global-collaboration-210610139.html
Excellent! Partnership with Biogen!
IMO they'd (PFE) be getting a steal at these prices
The CEO (of whom I am not fond of) stated years ago they were not for sale.
Who knows with bio-pharmas. Stuff you think will never be considered gets sold for huge valuations, and those that you think would/should be candidates just languish.
SGMO
Some coments in stocktwits about PFIZER BUYOUT
PFIZER could buy SGMO?
Any opinion?
Unfortunately
The CEO and the IR/PR dude need to be booted .... this has happened too often ....
well, that was a big fizzle.
Awesome background on ASH and SGMO here
https://twitter.com/_B_I_O_T_E_C_H_
"Top Notch Program, Platform and Leadership
The SB 525 dataset provides evidence that Sangamo has a best in class:
Therapy
Platform
Leadership"
https://www.investorvillage.com/smbd.asp?mb=1933&mn=138068&pt=msg&mid=20064375
Followers
|
85
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
878
|
Created
|
09/09/04
|
Type
|
Free
|
Moderators |
http://www.sangamo.com/index.php
http://finance.yahoo.com/q/ks?s=SGMO+Key+Statistics
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company?s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington?s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |